SCHEMBL10149784

SCHEMBL10149784

CS(=O)(=O)Nc1cc(-c2n[nH]c(=O)c3ccccc23)ccc1N1CCCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CREBBP Q92793 3/20 0.52
▸ BRD4 O60885 1/20 0.52
▸ CECR2 Q9BXF3 1/20 0.52
▸ BRD9 Q9H8M2 1/20 0.52
▸ ROCK2 O75116 1/20 0.48
▸ ROCK1 Q13464 1/20 0.48
▸ MAPT P10636 7/20 0.47
▸ HTT P42858 4/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MAPK1 P28482 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10149785 0.87 ROCK2 (0.46) CREBBPBRD4CECR2BRD9ROCK2
SCHEMBL10149777 0.83 MAPT (0.66) CREBBPROCK2ROCK1MAPTHTT
SCHEMBL10149767 0.80 HTT (0.52) ROCK2ROCK1MAPTHTTSMN1; SMN2
SCHEMBL10149809 0.79 POLB (0.64) ROCK2ROCK1MAPTHTTSMN1; SMN2
SCHEMBL10149736 0.79 POLB (0.64) ROCK2ROCK1MAPTHTTSMN1; SMN2
SCHEMBL10149762 0.79 MAPT (0.51) CREBBPROCK2ROCK1MAPTHTT
SCHEMBL10149760 0.79 MAPT (0.51) ROCK2ROCK1MAPTHTTSMN1; SMN2
SCHEMBL10149773 0.79 ROCK1 (0.52) CREBBPROCK2ROCK1MAPTHTT
SCHEMBL12909290 0.78 POLB (0.65) ROCK2ROCK1MAPTHTTSMN1; SMN2
SCHEMBL10149774 0.77 ROCK2 (0.49) ROCK2ROCK1MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171419-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP (US) 2014-06-19 — — US disclosed
US-20120190668-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-07-26 — — US disclosed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
WO-2011019400-A2 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP. (US) 2011-02-17 — — WO disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY ANGION BIOMEDICA CORP. (US) 2010-06-03 — — US disclosed
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY ANGION BIOMEDICA CORP. (US) 2010-06-03 — — US disclosed
US-7648978-B2 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone ANGION BIOMEDICA CORP. (US) 2010-01-19 — — US disclosed
US-7648978-B2 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone ANGION BIOMEDICA CORP. (US) 2010-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190668-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, HGFAC CREBBP 375/4885BRD4 2002/4885CECR2 2282/4885
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY HGF, IL2, IL2RA CREBBP 1034/4885BRD4 2352/4885CECR2 1940/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC CREBBP 707/4885BRD4 4007/4885CECR2 1030/4885
US-20140171419-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, MET CREBBP 238/4885BRD4 2312/4885CECR2 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback